Autophagy Suppresses Tumorigenesis of Hepatitis B Virus-associated Hepatocellular Carcinoma Through Degradation of MicroRNA-224
Overview
Authors
Affiliations
Unlabelled: In hepatocellular carcinoma (HCC), dysregulated expression of microRNA-224 (miR-224) and impaired autophagy have been reported separately. However, the relationship between them has not been explored. In this study we determined that autophagy is down-regulated and inversely correlated with miR-224 expression in hepatitis B virus (HBV)-associated HCC patient specimens. These results were confirmed in liver tumors of HBV X gene transgenic mice. Furthermore, miR-224 was preferentially recruited and degraded during autophagic progression demonstrated by real-time polymerase chain reaction and miRNA in situ hybridization electron microscopy after extraction of autophagosomes. Our in vitro study demonstrated that miR-224 played an oncogenic role in hepatoma cell migration and tumor formation through silencing its target gene Smad4. In HCC patients, the expression of low-Atg5, high-miR-224, and low-Smad4 showed significant correlation with HBV infection and a poor overall survival rate. Autophagy-mediated miR-224 degradation and liver tumor suppression were further confirmed by the autophagy inducer amiodarone and miR-224 antagonist using an orthotopic SD rat model.
Conclusion: A noncanonical pathway links autophagy, miR-224, Smad4, and HBV-associated HCC. These findings open a new avenue for the treatment of HCC.
Dong Y, He Y, Geng Y, Wei M, Zhou X, Lian J Cancer Cell Int. 2024; 24(1):328.
PMID: 39342235 PMC: 11439232. DOI: 10.1186/s12935-024-03503-1.
Hu Y, Zhao Y, Yan J, Ma C World J Clin Cases. 2024; 12(14):2404-2411.
PMID: 38765738 PMC: 11099406. DOI: 10.12998/wjcc.v12.i14.2404.
Yousefi P, Tabibzadeh A, Jawaziri A, Mehrjoo M, Akhavan M, Allahqoli L Immun Inflamm Dis. 2024; 12(2):e1182.
PMID: 38353395 PMC: 10865419. DOI: 10.1002/iid3.1182.
Song H, Zhao Z, Ma L, Zhao W, Hu Y, Song Y Oncogene. 2024; 43(11):821-836.
PMID: 38280941 PMC: 10920198. DOI: 10.1038/s41388-024-02950-4.
Current trends and future prospects of drug repositioning in gastrointestinal oncology.
Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.
PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.